Medicine
BYNFEZIA Pen 7 mg/2.8 mL injection
BYNFEZIA Pen 7 mg/2.8 mL injection is a prescription medicine containing Octreotide for subcutaneous use, marketed by Sun Pharmaceutical Industries, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Before first use, store BYNFEZIA PEN in the refrigerator between 2°C to 8°C…
Key facts
- Active ingredient (INN)
- Octreotide
- Brand
- BYNFEZIA Pen
- Strength
- 7 mg/2.8 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 cartridge of 2.8 mL, 2 cartridges of 2.8 mL
- Marketing authorisation holder
- Sun Pharmaceutical Industries
- Manufacturer
- Sun Pharmaceutical IndustriesIndia
- Origin register
- US FDA, United States
- Storage
- Before first use, store BYNFEZIA PEN in the refrigerator between 2°C to 8°C (36°F to 46°F) and store in outer carton in order to protect from light. Do not freeze. After first use, store pens at controlled room temperature between 20°C to 25°C (68°F to 77°F). Excursions between 15°C (59°F) and 30°C (86°F) are allowed for up to 28 days.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- H01CB02 Octreotide
- HS code (indicative)
- 3004.39Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 24 February 2025
- Identifiers
- RxCUI 2360543, 2360548DailyMed set ID 20ed4e79-ad4c-426f-859d-83790c00439bNDC 62756-452Application NDA213224
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 cartridge in 1 carton / 2.8 mL in 1 cartridge | 62756-452-36 | Sun Pharmaceutical IndustriesIndia | 24 February 2025 |
| 2 cartridge in 1 carton / 2.8 mL in 1 cartridge | 62756-452-37 | Sun Pharmaceutical IndustriesIndia | 24 February 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Octreotide
Clinical summary
Octreotide is a somatostatin analog indicated to reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1, somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection. MedsAcross supplies Octreotide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about OctreotideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Sandostatin prescribing information (Novartis Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Oczyesa: European public assessment report (EPAR) · European Medicines Agency
Need BYNFEZIA Pen 7 mg/2.8 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.